TS-1: Global Drug Analysis (2016-2017) with Forecasts to 2025 - ResearchAndMarkets.com

DUBLIN--()--The "Drug analysis: TS-1" drug pipelines has been added to ResearchAndMarkets.com's offering.

TS-1 (Otsuka/Nordic Group) is an orally available cytotoxic drug that contains gimeracil, oteracil potassium, and tegafur as active ingredients.

TS-1 inhibits DNA replication, a process that is crucial for cell proliferation and tumor growth. Tegafur is a prodrug that is converted to 5-fluorouracil (5-FU) in the body, which is an irreversible inhibitor of thymidylate synthase, an enzyme that is essential for DNA replication. Gimeracil enhances the anti-tumor effects of 5-FU by preventing its degradation within cells. Oteracil potassium reduces the serious gastrointestinal (GI) toxicity caused by 5-FU by inhibiting the phosphorylation of 5-FU in the GI tract.

Key Topics Covered:

Product Profiles

TS-1: Colorectal cancer (CRC)

TS-1: Pancreatic cancer

List of Figures

Figure 1: TS-1 for colorectal cancer - SWOT analysis

Figure 2: Drug assessment summary of TS-1 in colorectal cancer

Figure 3: Drug assessment summary of TS-1 in colorectal cancer

Figure 4: TS-1 sales for colorectal cancer in Japan, 2016-25

Figure 5: TS-1 for pancreatic cancer - SWOT analysis

Figure 6: Drug assessment summary of TS-1 in pancreatic cancer

List of Tables

Table 1: TS-1 drug profile

Table 2: TS-1 pivotal trial data in colorectal cancer

Table 3: TS-1 sales for colorectal cancer in Japan ($m), 2016-25

Table 4: Patients treated with TS-1 in Japan, 2016-25

Table 5: TS-1 drug profile

Table 6: TS-1 pivotal trial data in pancreatic cancer

Table 7: TS-1 other clinical trial data in pancreatic cancer

Table 8: TS-1 ongoing clinical trials in pancreatic cancer

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/gdth3n/ts1_global_drug?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs